Article
Tumor-derived death receptor 6 modulates dendritic cell development.
Cancer immunology, immunotherapy : CII - 1 Jun 2008
DeRosa David C, Ryan Paul J, Okragly Angela, Witcher Derrick R, Benschop Robert J
Abstract excerpt
Studies in murine models of cancer as well as in cancer patients have demonstrated that the immune response to cancer is often compromised. This paradigm is viewed as one of the major mechanisms of tumor escape. Many therapies focus on employing the professional antigen presenting dendritic cells (DC) as a strategy to overcome immune inhibition in cancer patients. Death receptor 6 (DR6) is an orphan member of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
